Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.

Abstract

Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.

• Authors: Mark D Lacy, Jason D Maguire, Mazie J Barcus, Judith Ling, Michael J Bangs, Robert Gramzinski, Hasan Basri, Priyanto Sismadi, Gerri B Miller, Jeffrey D Chulay, David J Fryauff, Stephen L Hoffman, J Kevin Baird
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 35 Issue 9 Pg. e92-5 (Nov 01 2002) ISSN: 1537-6591 [Electronic] United States
• PMID: 12384852 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antimalarials
• Naphthoquinones
• Proguanil
• Atovaquone

Topics

• Adolescent
• Adult
• Aged
• Animals
• Antimalarials (therapeutic use)
• Atovaquone
• Double-Blind Method
• Drug Resistance
• Drug Therapy, Combination
• Female
• Humans
• Indonesia (epidemiology)
• Malaria, Falciparum (drug therapy, immunology)
• Malaria, Vivax (drug therapy, immunology)
• Male
• Middle Aged
• Naphthoquinones (therapeutic use)
• Plasmodium falciparum (drug effects)
• Plasmodium vivax (drug effects)
• Proguanil (therapeutic use)
• Treatment Outcome